Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent, thanks for posting NR. Had missed that over the weekend. Love Leo's enthusiasm for their pipeline/trial results thus far and his willingness to answer questions from average investors.
Would this indicate that they were visiting Dr Reddy's?
Thanks for posting wild
Marketing and Manufacturing costs are quite significant. A partner that would cover those costs really helps cut the burden of funding the ramp up of those areas, as well as recruiting/finding the talent to spearhead the added corporate structure.
Wow thanks for the heads up Citrati, may have to call my broker!
OT: Team reports breakthrough in microring laser cavities
"Moreover, the demonstrated single-mode operation regardless of gain spectral bandwidth may create a laser chip carrying trillions of informational signals at different frequencies. This would make it possible to shrink a huge datacenter onto a tiny photonic chip."
Read more at: http://phys.org/news/2014-10-lord-microrings-team-breakthrough-microring.html#jCp
Young enough to have time to wait, but I've been invested since 2008 all the while hearing claims from management that we are always only a quarter away...and it still is another few quarters away. Today I'm being a bit whiney, like I said in my post. Honest enough to realize it and know I'm being a bit unreasonable with my criticisms of the PR. Absolutely no need to reply, sometimes you just need to vent. I had expected a lot more out of them this year, right or wrongfully, unfortunately.
And now we wait until January for results...then they will send out samples to potential customers...those potential customers will take a couple months to do their own tests and evaluations (and possibly request changes to the material/device)...then a couple more months for them to possibly enter negotiations for an order or partnership. Hopefully all goes well and maybe in 6-9 months we'll have our first order.
Was hoping they'd at least have mentioned something about improved materials since the ASM. At this point for me they are damned if they release any info and damned if they don't, but at least I'm honest when I'm being whiney. And, at least they are finally getting to the point where they will be demonstrating actual working devices with their material in it. Sigh, back to waiting...
From what I can recall, the correspondence implied that it would be at least 30 days until the wafers arrive...could be wrong, but if not we could be facing a longer wait. Seems likely that they should be received prior to Thanksgiving break though.
Anyone think Leo is taking advantage of the price rise to tap Aspire Capital for cash? Could help explain why the price rise wasn't as dramatic as many expected, would help fund the many upcoming trials, and would give them a nice cash position from which to negotiate a partnership with a big pharma company for B.
The company that makes this is private unfortunately. I saw this last week and did a little digging:
http://www.oncotherapy.co.jp/eng/corporate/index.html
COPD is such an enormous market, I am very excited about this as well. I can't wait to hear more details about future trials for this indication especially since this is a relatively better known and understood disease as compared to others.
For ABSSSI PH3 trials, we would not have to prove superiority of cure rate in comparison to Daptomycin, right? Do we have any recent examples of the Primary and Secondary endpoints for ph 3 ABSSSI trials? I know there were a couple companies that had recent FDA approvals but I can't remember their names off the top of my head in order to check clinicaltrials.gov
Article: Researchers increase the switching contrast of an all-optical flip-flop
Researchers at the Rochester Institute of Technology in New York have increased the switching contrast of a particular kind of all-optical flip-flop by 28 dB, resulting in a switching contrast of 36.6 dB. This could provide a huge leap in the performances of a range of photonic techniques, such as all-optical packet switching, all-optical label addressing, and square-wave clock generation, as well as other photonic devices housing semiconductor optical amplifiers or even passive nonlinear media.
http://phys.org/news/2014-10-contrast-all-optical-flip-flop.html
Can anyone shed some light on what this means (from the 8-K this morning):
"The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference."
Cubist days are numbered....Somewhere around 2 years from now until B would hit the market???
"There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator."
I'd love to be wrong cool-air. I still have 1/3 of my original position left here. My assumption is that their estimations from back in August did not take into account 2-3 month delays from IMEC and OpSis.
Unless I'm losing my mind, they (including Tom) have given us plenty of milestone time frames before that haven't panned out...however, while my thoughts are founded on reasonable assumptions based on past performance they are IMO only so no need to get up in arms.
And yes, I chose the handle oddone33320 on purpose so when-you-spell-it-out-it-does-not-offend-me-by-calling-me-odd.
Have a great weekend all
I'd be shocked if they were on time with those demonstrations, especially given that they won't receive the shipments from IMEC or OpSis until November at the earliest.
I'm expecting the next piece of news to be the 10-Q in early November followed by the usual mid-December progress re-cap for the year that also includes future projections for 2015. We are fast approaching holiday season and we know that during that time everything slows down significantly.
When is the new study expected to start?
Does anyone have an idea of the size of the medical imaging agents market? I'm curious what kind of potential revenue CLRB could see for this side of their pipeline. Also feel like this will be their first product to market.
It's normal for the share price to take a hit after either a reverse split or a capital raise and CLRB did BOTH in a relatively short period of time recently so I was expecting this. If you are looking to be in CLRB for at least a year this is a good buying opportunity, otherwise traders should probably look elsewhere.
Great,thanks Karin. Wasn't sure how it was viewed in the later trials.
How does management plan to scale up production of their FluCides drug quantities? Is there a plan in place?
Hopefully we don't have to wait until the annual December, year-end shareholder letter to get our next update.
I seem to recall a few on this board saying that we are still at least a month away from receiving the shipments from IMEC and OpSis?
With regard to the single, possible SAE in the Brilacidin trial what are the implications if it was in one of the B arms? Specifically, with regard to FDA and moving forward into Phase 3? Does it take more than 1 SAE to be considered a cause for concern by the FDA when planning additional trials?
What's the connection between the two?
Great to hear, thanks for the reply BK
Don't they still need to formulate the mouth rinse for B-OM or is that piece all squared away?
Didn't the company say during the ASM that they were in the process of coming out with new materials with better properties as designed by the new modeling software? Kind of thought we would hear something about that now, especially in the absence of anything else. It's been over a month since the last PR, usually we get at least one per month.
The share price here is starting to look very attractive for what I perceive to be a future blockbuster cancer treatment. Granted, they still haven't entered their P2 trials yet for cancer treatment but the results to date show unconditionally that their treatment is highly selective in targeting cancer cells,so much so that even cancer STEM cells are targeted as well. I do find it strange that they selected Multiple Myeloma for the P2 trial but I'm sure they have a good reason for it and hopefully saw great pre-clinical efficacy in an animal model...haven't bothered to send an email to IR requesting an explanation though
Is there a chance that the "possible SAE" was in the Dapto arm? Either way, there was only one and if related to Brila it was only in one arm of which we may not go with in a phase 3 anyway.
Thanks gov, and I think you are right
Did Celgene or any other similar "story stocks" receive buyout offers near this stage of development? Just curious if/when CTIX might possibly start receiving offers from large pharmas...
Just like all his other form 4s:
"Explanation of Responses:
( 1) Acquired directly from the issuer in connection with Operations Committee work."
Next week is "early fall" and a week after that is Q4 so hopefully they finally meet or exceed their own estimates on when the devices will be ready for demonstration...
Does anyone know how much is still available from Aspire? Just wondering how much left there is to tap for the upcoming trials. I assume CTIX will be able to take advantage of share sales at a higher price in the near future!
TIA
I haven't followed this company in a while. Do we have any indication that our situation is different than that of GALE with regard to the Dream Team/Financing debacle?
I'd certainly like to invest more but have no inkling as to where the chips will fall with regard to all the lawsuits etc. If anyone can shed some light on this I'd appreciate it.
TIA
What is the half-life of K? I thought that this was fairly short but can't remember off the top of my head...
What will be interesting to me is when they up the dosing FREQUENCY of K in one/more of their trials, in-combination or alone.
TIA